Monaco M, Filpi G, Kohler S, Eversole R, Idris O, Essani K
Pathogens. 2024; 13(5).
PMID: 38787254
PMC: 11124456.
DOI: 10.3390/pathogens13050402.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T
Int J Clin Oncol. 2023; 28(8):941-955.
PMID: 37300720
PMC: 10390617.
DOI: 10.1007/s10147-023-02360-8.
DeLucia D, Lee J
Cancer Treat Res. 2022; 183:1-48.
PMID: 35551655
DOI: 10.1007/978-3-030-96376-7_1.
Check J, Check D
Int J Mol Sci. 2021; 22(22).
PMID: 34830233
PMC: 8621132.
DOI: 10.3390/ijms222212351.
Buchler T, Vasek P, Spisek R, Skrobanek P, Horejsi V
Oncoimmunology. 2018; 8(1):e1526614.
PMID: 30546967
PMC: 6287775.
DOI: 10.1080/2162402X.2018.1526614.
Rejection versus escape: the tumor MHC dilemma.
Garrido F, Ruiz-Cabello F, Aptsiauri N
Cancer Immunol Immunother. 2017; 66(2):259-271.
PMID: 28040849
PMC: 11028748.
DOI: 10.1007/s00262-016-1947-x.
Cancer and the Immune System: Basic Concepts and Targets for Intervention.
Pardoll D
Semin Oncol. 2015; 42(4):523-38.
PMID: 26320058
PMC: 5595144.
DOI: 10.1053/j.seminoncol.2015.05.003.
Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
Lopes L, Fletcher K, Ikeda Y, Collins M
Cancer Immunol Immunother. 2005; 55(8):1011-6.
PMID: 16311731
PMC: 11030885.
DOI: 10.1007/s00262-005-0095-5.
Some aspects of the problem of immunity against transplanted and spontaneous tumors.
Hirsch H
Bacteriol Rev. 1962; 26:336-53.
PMID: 13961186
PMC: 441155.
DOI: 10.1128/br.26.3.336-353.1962.
Tumor isoimmunity.
Hirsch H
Experientia. 1958; 14(8):269-71.
PMID: 13574129
DOI: 10.1007/BF02166989.
Failure to demonstrate tumour-associated transplantation antigens on asbestos-induced mesotheliomas in rats.
Brown D, Wagner J, Wagner M
Br J Cancer. 1980; 42(5):797-801.
PMID: 7459217
PMC: 2010543.
DOI: 10.1038/bjc.1980.316.
Purification and biochemical properties of tumor-associated transplantation antigens from methylcholanthrene-induced murine sarcomas.
DuBois G, Law L, Appella E
Proc Natl Acad Sci U S A. 1982; 79(24):7669-73.
PMID: 6961442
PMC: 347409.
DOI: 10.1073/pnas.79.24.7669.
Manipulation of host resistance in cancer therapy.
Baldwin R
Springer Semin Immunopathol. 1982; 5(2):113-25.
PMID: 6755781
DOI: 10.1007/BF00199791.
Generation of TSTA diversity. Looking for testable hypotheses.
Parmiani G, Pierotti M
Cancer Immunol Immunother. 1983; 14(3):133-6.
PMID: 6340823
PMC: 11039059.
DOI: 10.1007/BF00205350.
Specificity of tumour associated transplantation antigens (TATA) of different clones from the same tumour.
Woodruff M, Ansell J, Hodson B, Micklem H
Br J Cancer. 1984; 49(1):5-10.
PMID: 6197985
PMC: 1976682.
DOI: 10.1038/bjc.1984.2.
The presence of tumour-specific membrane antigen in the serum of rats with chemically induced sarcomata.
Thomson D, Steele K, Alexander P
Br J Cancer. 1973; 27(1):27-34.
PMID: 4568460
PMC: 2008825.
DOI: 10.1038/bjc.1973.4.
Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.
Stauss H, Van Waes C, Fink M, Starr B, Schreiber H
J Exp Med. 1986; 164(5):1516-30.
PMID: 3490532
PMC: 2188451.
DOI: 10.1084/jem.164.5.1516.
